+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gynaecology Drugs Market Report and Forecast 2023-2031

  • PDF Icon


  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855130
The global gynaecology drugs market was valued at USD 26.9 billion in 2022, driven by the rising prevalence of gynaecological disorders across the globe. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2023-2031 to achieve a value of USD 45.7 billion by 2031.

Gynaecology Drugs: Introduction

Gynaecology drugs play a crucial role in the diagnosis, treatment, and management of various gynecological conditions and disorders. These drugs are specifically formulated to address the unique needs of women's reproductive health and aim to provide relief from symptoms, regulate hormone levels, and improve overall well-being.

Gynecological health is of utmost importance to women, as it directly impacts their quality of life and reproductive capabilities. Gynaecology drugs encompass a wide range of therapeutic areas, including hormonal therapies, contraceptives, fertility treatments, menopausal management, and drugs for conditions such as endometriosis, polycystic ovary syndrome (PCOS), and gynecological cancers.

The field of Gynaecology drugs is continuously evolving, driven by advancements in medical research, technology, and a better understanding of women's health. New treatment options and drug formulations are being developed to address the specific needs and preferences of patients, with a focus on personalized medicine and tailored treatment approaches.

Key Trends in the Gynaecology Drugs Market

Some key trends involved in the gynaecology drugs market are as follows:
  • Increasing demand for personalized medicine: There is a growing trend towards personalized medicine in Gynaecology, where treatment approaches are tailored to the individual needs and characteristics of each patient. This includes the use of genetic testing, biomarkers, and advanced diagnostic tools to identify the most effective treatment options for specific gynecological conditions
  • Rising focus on non-hormonal and natural alternatives: Many women are seeking non-hormonal and natural alternatives for managing gynecological conditions, such as herbal supplements, acupuncture, and lifestyle modifications. This trend is driven by concerns about the potential side effects of hormonal therapies and a desire for more natural and holistic approaches to women's health
  • Advancements in fertility treatments: The field of fertility treatments is witnessing significant advancements, with the development of new assisted reproductive technologies, such as in vitro fertilization (IVF), preimplantation genetic testing, and egg freezing. These advancements are aimed at improving success rates, enhancing patient experience, and expanding access to fertility treatments
  • Increasing focus on women's sexual health: There is a growing recognition of the importance of women's sexual health and the need for effective treatments for sexual dysfunctions and disorders. This has led to the development of new drugs and therapies targeting conditions such as hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD)

Gynaecology Drugs Market Segmentations

Market by Therapy Type
  • Hormonal Therapy
  • Non-Hormonal Therapy

Market Breakup by Indication

  • Gynaecology Cancers
  • Endometriosis
  • Female Infertility
  • Menopausal Disorder
  • Gynaecology Infections
  • Polycystic Ovary Syndrome (PCOS)
  • Contraception
  • Other Indication

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Intravaginal
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Research Institute
  • Home Healthcare
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Gynaecology Drugs Market Scenario

The gynaecology drugs market is driven by several factors, including the rising prevalence of gynaecological disorders, increasing awareness and education about women's health, advancements in medical technology, and evolving societal and cultural factors. The market is characterized by a wide range of drugs, including hormonal therapies, contraceptives, fertility drugs, hormone replacement therapies, and medications for the treatment of gynaecological cancers and infections.

There is a growing demand for innovative and targeted therapies that offer better efficacy, fewer side effects, and improved patient outcomes. Pharmaceutical companies are investing in research and development to bring novel drugs to market, focusing on areas such as personalized medicine, non-hormonal treatment alternatives, fertility treatments, and women's sexual health. Additionally, advancements in medical technology, such as minimally invasive surgical techniques and robotic-assisted surgeries, are driving the demand for complementary pharmaceutical interventions.

Market competition is high, with both established pharmaceutical companies and emerging players striving to capture a share of the market. Companies are investing in product innovation, clinical trials, and strategic partnerships to gain a competitive edge. Moreover, increasing government initiatives, healthcare reforms, and insurance coverage for gynaecology drugs are expected to further boost market growth.

Gynaecology Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Eli Lilly and Company
  • Pfizer, Inc
  • Amgen Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Allergan Plc
  • Bayer AG Financial Analysis
  • AbbVie Inc
  • Lupin Pharmaceuticals Inc
  • Therapeutics MD Inc
  • Ferring Holding S.A
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gynaecology Drugs Market Overview
3.1 Global Gynaecology Drugs Market Historical Value (2016-2022)
3.2 Global Gynaecology Drugs Market Forecast Value (2023-2031)
4 Global Gynaecology Drugs Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Gynaecology Drugs Market Segmentation
5.1 Global Gynaecology Drugs Market by Therapy Type
5.1.1 Market Overview
5.1.2 Hormonal Therapy
5.1.3 Non-Hormonal Therapy
5.2 Global Gynaecology Drugs Market by Indication
5.2.1 Market Overview
5.2.2 Gynaecology Cancers
5.2.3 Endometriosis
5.2.4 Female Infertility
5.2.5 Menopausal Disorder
5.2.6 Gynaecology Infections
5.2.7 Polycystic Ovary Syndrome (PCOS)
5.2.8 Contraception
5.2.9 Other Indication
5.3 Global Gynaecology Drugs Market by Route of Administration
5.3.1 Market Overview
5.3.2 Oral
5.3.3 Parenteral
5.3.4 Intravaginal
5.3.5 Others
5.4 Global Gynaecology Drugs Market by Distribution Channel
5.4.1 Market Overview
5.4.2 Hospital Pharmacy
5.4.3 Retail Pharmacy
5.4.4 Online Pharmacies
5.4.5 Others
5.5 Global Gynaecology Drugs Market by End User
5.5.1 Market Overview
5.5.2 Hospitals
5.5.3 Specialty Clinics
5.5.4 Diagnostic Centers
5.5.5 Research Institute
5.5.6 Home Healthcare
5.5.7 Others
5.6 Global Gynaecology Drugs Market by Region
5.6.1 Market Overview
5.6.2 North America
5.6.3 Europe
5.6.4 Asia Pacific
5.6.5 Latin America
5.6.6 Middle East and Africa
6 North America Gynaecology Drugs Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Gynaecology Drugs Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Gynaecology Drugs Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Gynaecology Drugs Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Gynaecology Drugs Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.5 Others
16 Supplier Landscape
16.1 Eli Lilly and Company
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 Pfizer, Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Amgen Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 AstraZeneca
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 F. Hoffmann-La Roche Ltd.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Allergan Plc
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Bayer AG Financial Analysis
16.7.1 Product Portfolio
16.7.2 Demographic Reach and Achievements
16.7.3 Mergers and Acquisitions
16.7.4 Certifications
16.8 AbbVie Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Lupin Pharmaceuticals Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Therapeutics MD Inc.
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Ferring Holding S.A.
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 Teva Pharmaceutical Industries Limited
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
16.13 Addex Therapeutics Ltd.
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.13.5 Certifications
17 Global Gynaecology Drugs Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Eli Lilly and Company
  • Pfizer, Inc.
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Allergan Plc
  • Bayer AG Financial Analysis
  • AbbVie Inc.
  • Lupin Pharmaceuticals Inc.
  • Therapeutics MD Inc.
  • Ferring Holding S.A.
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.



Table Information